Cancer & Disease Research
Beyond capital -- what it takes for biopharma startups to succeed
Investors are more interested in the biopharmaceutical sector than ever before. But success for biopharma startups means more than just securing investment funds -- it requires successful product commercialization. A panel of biopharmaceutical and finance executives discussed the factors that go into ensuring success on January 12 at the Biotech Showcase virtual event.  Discuss
Development 'cookbooks' could speed up gene therapy
Great strides have been made in the development of gene editing tools in the past decade, but translating the technology into real therapies to treat patients has taken longer than expected. How to accelerate this process was the subject of a panel discussion on January 13 at the Biotech Showcase virtual event.  Discuss
How is the pharma-AI partnership landscape changing?
Artificial intelligence (AI) is taking on a growing role in drug discovery and development, with some 250 firms in a market space that's worth over $9 billion. And developers of AI are becoming attractive acquisition targets for contract research organizations, according to Ulrik Kristensen, PhD, research analyst and founder of Emersion Insights.  Discuss
What makes immuno-oncology therapies attractive investments?
Although immuno-oncology therapies have been around for many years, investors are excited to partner with innovators in the space who can push the boundaries of what these therapies are able to achieve. A panel of investors and business development executives discussed what exactly makes a specific candidate attractive as a business opportunity during a recorded session at the Biotech Showcase virtual event.  Discuss
Tackling the next hurdle in cell and gene therapy: Manufacturing
Although innovation continues to occur at lightning fast speeds in the cell and gene therapy space, commercialization and manufacturing of these technologies is still playing catch-up. A group of investors and executives from across the industry discussed this issue in an on-demand session of the Biotech Showcase virtual event.  Discuss
How can biopharma innovation be maintained after COVID-19?
Will the speed of biotech innovation seen during the COVID-19 pandemic be maintained going forward, or will the market revert to the status quo? A panel of speakers discussed these questions during a January 7 advance session of the Biotech Showcase, a virtual event to be held January 11-15.  Discuss
Are biotech companies really high-risk investments?
Despite the public perception of the biotech industry as a high-risk investment, a new analysis published in PLOS One on January 6 found that over the long term, biotech firms that went public performed just as well as nonbiotech companies by various measures of financial success.  Discuss
Top Operation Warp Speed official shares lessons learned from COVID-19
The global COVID-19 pandemic has placed an urgent burden on governments to serve society, and with the help of the biotechnology and pharmaceutical industries, the job is getting done. That's according to Moncef Slaoui, PhD, chief adviser of the U.S. government's Operation Warp Speed project, who discussed his unique experiences at an advance session of the Biotech Showcase virtual event on January 5.  Discuss
COVID-19 to have long-lasting effect on biotech industry
The COVID-19 pandemic will have a widespread and long-lasting effect on the biotechnology industry, according to speakers at a January 5 presentation held in advance of the Biotech Showcase virtual event taking place January 11-15. Biotech companies have pivoted on a massive scale to pursue infectious disease research -- and not all of them will be successful.  Discuss
Allergic reactions to COVID-19 vaccines shouldn't stop vaccinations
COVID-19 vaccines currently approved for emergency use by the U.S. Food and Drug Administration are safe even among people with food or medication allergies, according to allergists from Massachusetts General Hospital. A review of all relevant information was published in the Journal of Allergy and Clinical Immunology: In Practice on December 31.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter